LORBRENA® (Lorlatinib)

The FDA on March 3, 2021 granted regular approval to LORBRENA® for patients with metastatic Non-Small Cell Lung Cancer (NSCLC) whose tumors are Anaplastic Lymphoma Kinase (ALK)-positive, detected by an FDA-approved test. LORBRENA® is a product of Pfizer Inc.